• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    B. Riley Securities initiated coverage on Lantheus Holdings with a new price target

    5/9/22 7:14:08 AM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $LNTH alert in real time by email
    B. Riley Securities initiated coverage of Lantheus Holdings with a rating of Buy and set a new price target of $91.00
    Get the next $LNTH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LNTH

    DatePrice TargetRatingAnalyst
    12/18/2024$143.00Buy
    Goldman
    9/3/2024$175.00Buy
    Redburn Atlantic
    7/10/2024$100.00 → $130.00Mkt Outperform
    JMP Securities
    12/18/2023Outperform → Mkt Perform
    William Blair
    12/4/2023$100.00Outperform
    TD Cowen
    9/29/2023Outperform
    William Blair
    3/8/2023$120.00Mkt Outperform
    JMP Securities
    11/30/2022Outperform
    SVB Leerink
    More analyst ratings

    $LNTH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Lantheus Announces Presentations to be featured at the 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting

      BEDFORD, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced the presentation of new data highlighting two oncology radiodiagnostic agents will be presented at the upcoming 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, taking place June 21-24, 2025, in New Orleans, LA. Presentation details are as follows: Oral Presentations Date & Time: Tuesday, June 24, 2025; 2:30 – 3:35 PM CTSession Number: SS39Session Title: Advancing Radiopharmaceutical Production, Qu

      6/11/25 4:01:00 PM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Lantheus to Present at the 2025 Truist Securities MedTech Conference

      BEDFORD, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced Brian Markison, Chief Executive Officer, will present at the 2025 Truist Securities MedTech Conference at 8:40 a.m. ET on Tuesday, June 17. To access a live webcast of the presentation, please visit the Investors section of the Company's website at www.lantheus.com. A replay of the webcast will be available on the Company's website for at least 30 days following the live presentation. About Lantheus Lantheus is the leading

      6/10/25 8:30:00 AM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Lantheus to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025

      BEDFORD, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced Brian Markison, Chief Executive Officer, will present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 at 2:40 p.m. ET on Tuesday, June 10. To access a live webcast of the presentation, please visit the Investors section of the Company's website at www.lantheus.com. A replay of the webcast will be available on the Company's website for at least 30 days following the live presentation. About Lantheus Lanthe

      6/3/25 8:30:00 AM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $LNTH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Officer Niedzwiecki Daniel sold $472,440 worth of shares (6,000 units at $78.74), decreasing direct ownership by 6% to 87,057 units (SEC Form 4)

      4 - Lantheus Holdings, Inc. (0001521036) (Issuer)

      6/17/25 4:31:48 PM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Director Mchugh Julie sold $423,771 worth of shares (5,192 units at $81.62), decreasing direct ownership by 17% to 25,962 units (SEC Form 4)

      4 - Lantheus Holdings, Inc. (0001521036) (Issuer)

      6/11/25 4:33:01 PM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • CFO and Treasurer Marshall Robert J. Jr. exercised 14,773 shares at a strike of $49.93 and sold $3,301,296 worth of shares (39,773 units at $83.00), decreasing direct ownership by 22% to 88,860 units (SEC Form 4)

      4 - Lantheus Holdings, Inc. (0001521036) (Issuer)

      6/11/25 4:32:44 PM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $LNTH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Lantheus Alpha Therapy, Llc bought $57,409,487 worth of shares (60,431,039 units at $0.95) (SEC Form 4)

      4 - Lantheus Holdings, Inc. (0001521036) (Reporting)

      3/8/24 11:24:53 AM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $LNTH
    SEC Filings

    See more
    • SEC Form 144 filed by Lantheus Holdings Inc.

      144 - Lantheus Holdings, Inc. (0001521036) (Subject)

      6/9/25 10:06:49 AM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Lantheus Holdings Inc.

      SCHEDULE 13G/A - Lantheus Holdings, Inc. (0001521036) (Subject)

      6/6/25 11:59:42 AM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SD filed by Lantheus Holdings Inc.

      SD - Lantheus Holdings, Inc. (0001521036) (Filer)

      5/30/25 4:30:17 PM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care